PubMed=7510115; DOI=10.1038/bjc.1994.78; PMCID=PMC1968867
Mobus V.J., Moll R., Gerharz C.-D., Kieback D.G., Weikel W., Hoffmann G., Kreienberg R.
Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis.
Br. J. Cancer 69:422-428(1994)

PubMed=21559638; DOI=10.3892/ijo.5.4.753
Will C., Wilhelm O.G., Hohl S., Mobus V.J., Weidle U.H., Kreienberg R., Janicke F., Schmitt M., Graeff H.
Expression of urokinase-type plasminogen-activator (uPA) and its receptor (uPAR) in human ovarian-cancer cells and in-vitro invasion capacity.
Int. J. Oncol. 5:753-761(1994)

PubMed=11242531; DOI=10.1089/10430340150504019
Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J., Kreienberg R., Runnebaum I.B.
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001)

DOI=10.5282/edoc.3898
Euer N.I.
Identification of target genes for the therapy and diagnosis of ovarian carcinoma.
Thesis PhD (2005); Ludwig Maximilians University of Munich; Munich; Germany

PubMed=15706405; DOI=10.3892/or.13.3.375
Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R., Weidle U.H.
Identification of L1CAM, Jagged2 and neuromedin U as ovarian cancer-associated antigens.
Oncol. Rep. 13:375-387(2005)